Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

131.07USD
26 Jul 2017
Change (% chg)

-- (--)
Prev Close
$131.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,728,313
52-wk High
$145.41
52-wk Low
$96.18

Select another date:

Alexion posts higher second-quarter earnings on strong Soliris sales

NEW YORK Alexion Pharmaceuticals Inc posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.

Alexion posts higher Q2 earnings on strong Soliris sales

NEW YORK, July 27 Alexion Pharmaceuticals Inc posted a better than expected second-quarter profit on Thursday and raised its full-year forecast on strong sales of its expensive rare disease treatment Soliris.

BRIEF-Arbutus announces conclusion of LNP license agreement with Alexion

* Arbutus announces conclusion of LNP license agreement with Alexion

BRIEF-Blueprint Medicines to evaluate advance disease discovery program opportunities

* Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion

BRIEF-Alexion reaches funding agreement with NICE and NHS England for Strensiq

* Says has reached national funding agreement with NICE & NHS England based on Managed Access Agreement

BRIEF-Alexion receives positive CHMP opinion for Soliris in the EU

* Alexion receives positive CHMP opinion for Soliris (eculizumab) for the treatment of patients with refractory Generalized Myasthenia Gravis (GMG) in the European Union

Alexion taps Biogen veteran Paul Clancy as CFO

Alexion Pharmaceuticals Inc named long-time Biogen Inc Chief Financial Officer Paul Clancy to a similar position, effective July 31, as recently appointed CEO Ludwig Hantson steps up efforts to regain investor confidence.

UPDATE 1-Alexion taps Biogen veteran Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc named long-time Biogen Inc Chief Financial Officer Paul Clancy to a similar position, effective July 31, as recently appointed CEO Ludwig Hantson steps up efforts to regain investor confidence.

REFILE-Alexion names Biogen's Paul Clancy as CFO

June 13 Alexion Pharmaceuticals Inc on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31.

BRIEF-Alexion Pharmaceuticals in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million

* Alexion Pharmaceuticals Inc - in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million

Select another date: